1887

Abstract

Identification of B-cell epitopes facilitates the development of vaccines, therapeutic antibodies and diagnostic tools. Previously, the binding site of the bank vole monoclonal antibody (mAb) 4G2 against Puumala virus (PUUV, an orthohantavirus in the family of the order) was predicted using a combination of methods, including pepscan, phage-display, and site-directed mutagenesis of vesicular stomatitis virus (VSV) particles pseudotyped with Gn and Gc glycoproteins from PUUV. These techniques led to the identification of the neutralization escape mutation F915A. To our surprise, a recent crystal structure of PUUV Gc in complex with Fab 4G2 revealed that residue F915 is distal from epitope of mAb 4G2. To clarify this issue and explore potential explanations for the inconsistency, we designed a mutagenesis experiment to probe the 4G2 epitope, with three PUUV pseudoviruses carrying amino acid changes E725A, S944F, and S946F, located within the structure-based 4G2 epitope on the Gc. These amino acid changes were able to convey neutralization escape from 4G2, and S944F and S946F also conveyed escape from neutralization by human mAb 1C9. Furthermore, our mapping of all the known neutralization evasion sites from hantaviral Gcs onto PUUV Gc revealed that over 60 % of these sites reside within or close to the epitope of mAb 4G2, indicating that this region may represent a crucial area targeted by neutralizing antibodies against PUUV, and to a lesser extent, other hantaviruses. The identification of this site of vulnerability could guide the creation of subunit vaccines against PUUV and other hantaviruses in the future.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001901
2023-10-06
2024-10-05
Loading full text...

Full text loading...

References

  1. Sanchez-Trincado JL, Gomez-Perosanz M, Reche PA. Fundamentals and methods for T- and B-cell epitope prediction. J Immunol Res 2017; 2017:2680160 [View Article] [PubMed]
    [Google Scholar]
  2. Singh H, Gupta S, Gautam A, Raghava GPS. Designing B-cell epitopes for immunotherapy and subunit vaccines. Methods Mol Biol 2015; 1348:327–340 [View Article] [PubMed]
    [Google Scholar]
  3. Caoili SEC. Comprehending B-cell epitope prediction to develop vaccines and immunodiagnostics. Front Immunol 2022; 13:908459 [View Article] [PubMed]
    [Google Scholar]
  4. Potocnakova L, Bhide M, Pulzova LB. An introduction to B-cell epitope mapping and in silico epitope prediction. J Immunol Res 2016; 2016:6760830 [View Article] [PubMed]
    [Google Scholar]
  5. Vaheri A, Henttonen H, Mustonen J. Hantavirus research in Finland: highlights and perspectives. Viruses 2021; 13:1452 [View Article] [PubMed]
    [Google Scholar]
  6. Heiskanen T, Lundkvist A, Soliymani R, Koivunen E, Vaheri A et al. Phage-displayed peptides mimicking the discontinuous neutralization sites of puumala hantavirus envelope glycoproteins. Virology 1999; 262:321–332 [View Article] [PubMed]
    [Google Scholar]
  7. Levanov L, Iheozor-Ejiofor RP, Lundkvist Å, Vapalahti O, Plyusnin A. Defining of MAbs-neutralizing sites on the surface glycoproteins Gn and Gc of a hantavirus using vesicular stomatitis virus pseudotypes and site-directed mutagenesis. J Gen Virol 2019; 100:145–155 [View Article] [PubMed]
    [Google Scholar]
  8. Rissanen I, Stass R, Krumm SA, Seow J, Hulswit RJ et al. Molecular rationale for antibody-mediated targeting of the hantavirus fusion glycoprotein. Elife 2020; 9:e58242 [View Article] [PubMed]
    [Google Scholar]
  9. Krissinel E, Henrick K. Inference of macromolecular assemblies from crystalline state. J Mol Biol 2007; 372:774–797 [View Article] [PubMed]
    [Google Scholar]
  10. Hörling J, Lunkvist Å. Puumala virus antibody escape mutants: single amino acid substitutions in G1 and G2 eliminate important neutralization epitopes. Virus Res 1997; 45:29–44
    [Google Scholar]
  11. Paneth Iheozor-Ejiofor R, Levanov L, Hepojoki J, Strandin T, Lundkvist Å et al. Vaccinia virus-free rescue of fluorescent replication-defective vesicular stomatitis virus and pseudotyping with puumala virus glycoproteins for use in neutralization tests. J Gen Virol 2016; 97:1052–1059 [View Article] [PubMed]
    [Google Scholar]
  12. Ogino M, Ebihara H, Lee BH, Araki K, Lundkvist A et al. Use of vesicular stomatitis virus pseudotypes bearing hantaan or seoul virus envelope proteins in a rapid and safe neutralization test. Clin Diagn Lab Immunol 2003; 10:154–160 [View Article] [PubMed]
    [Google Scholar]
  13. Lundkvist A, Hörling J, Athlin L, Rosén A, Niklasson B. Neutralizing human monoclonal antibodies against puumala virus, causative agent of nephropathia epidemica: a novel method using antigen-coated magnetic beads for specific B cell isolation. J Gen Virol 1993; 74 (Pt 7):1303–1310 [View Article] [PubMed]
    [Google Scholar]
  14. Mittler E, Serris A, Esterman ES, Florez C, Polanco LC et al. Structural and mechanistic basis of neutralization by a pan-hantavirus protective antibody. Sci Transl Med 2023; 15:15 [View Article] [PubMed]
    [Google Scholar]
  15. Engdahl TB, Binshtein E, Brocato RL, Kuzmina NA, Principe LM et al. Antigenic mapping and functional characterization of human new world hantavirus neutralizing antibodies. Elife 2023; 12:e81743 [View Article] [PubMed]
    [Google Scholar]
  16. Mittler E, Wec AZ, Tynell J, Guardado-Calvo P, Wigren-Byström J et al. Human antibody recognizing a quaternary epitope in the Puumala virus glycoprotein provides broad protection against orthohantaviruses. Sci Transl Med 2022; 14:636 [View Article] [PubMed]
    [Google Scholar]
  17. Duehr J, McMahon M, Williamson B, Amanat F, Durbin A et al. Neutralizing monoclonal antibodies against the Gn and the Gc of the andes virus glycoprotein spike complex protect from virus challenge in a preclinical hamster model. mBio 2020; 11:e00028–20 [View Article]
    [Google Scholar]
  18. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM et al. UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem 2004; 25:1605–1612 [View Article] [PubMed]
    [Google Scholar]
/content/journal/jgv/10.1099/jgv.0.001901
Loading
/content/journal/jgv/10.1099/jgv.0.001901
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error